Unicycive Therapeutics jumps 71% on public debut (NASDAQ:UNCY)

Unicycive Therapeutics (UNCY), a biotech company focused on kidney disease medicines, fell slightly after gaining more than half of its value on Tuesday when it began trading after an initial public offering (IPO)./nRead More